Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers-Reference-Cited by-同舟云学术

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Published:2014-09-19 Issue:22 Volume:20 Page:5672-5685
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Yap Timothy A.,Yan Li,Patnaik Amita,Tunariu Nina,Biondo Andrea,Fearen Ivy,Papadopoulos Kyriakos P.,Olmos David,Baird Richard,Delgado Liliana,Tetteh Ernestina,Beckman Robert A.,Lupinacci Lisa,Riisnaes Ruth,Decordova Shaun,Heaton Simon P.,Swales Karen,deSouza Nandita M.,Leach Martin O.,Garrett Michelle D.,Sullivan Daniel M.,de Bono Johann S.,Tolcher Anthony W.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies;Diabetes Therapy;2024-07-31

2. A phase 2 study of MK‐2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104);Cancer;2023-11-10

3. The Chemoprevention of Hereditary Diffuse Gastric Cancer;Hereditary Gastric and Breast Cancer Syndrome;2023

4. Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy;JCO Precision Oncology;2022-06

5. Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic;Exploration of Targeted Anti-tumor Therapy;2022-04-24